Gemzar (Gemcitabine)

DRUG4 trials

Sponsors

Seagen Inc., Amer Zureikat, Chang Gung Memorial Hospital, ImmunoGenesis

Conditions

Cervical CancerOvarian NeoplasmsPancreatic AdenocarcinomaPancreatic Cancer

Phase 2

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

TerminatedNCT00051584

Seagen Inc.Ovarian Neoplasms

End: 2003-05-31Target: 60Updated: 2011-10-24

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

CompletedNCT00557492

Amer ZureikatPancreatic Cancer

Start: 2006-12-31End: 2016-12-31Updated: 2018-09-25

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

CompletedNCT01144455

ImmunoGenesisPancreatic Adenocarcinoma

Start: 2010-06-30End: 2014-12-31Updated: 2025-05-11

Phase 3

Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer

Chang Gung Memorial HospitalCervical Cancer

Start: 2009-02-28End: 2013-01-31Target: 172Updated: 2010-01-05

Related Papers

Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.

Journal of Clinical Oncology2018-05-2015 citations

MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2016-05-2071 citations

Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

Journal of Clinical Oncology2016-02-0134 citations

Abstract 2603: Combination activity of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor xenograft models

Cancer Research2015-08-01

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Cancer Biology & Therapy2015-02-1351 citations

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Journal of Clinical Oncology2014-12-16186 citations

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)

BMC Cancer2014-06-0781 citations

Abstract C287: Efficacy and safety of the TH-302, gemcitabine, and nab-paclitaxel combination in xenograft models of pancreatic cancer.

Molecular Cancer Therapeutics2013-11-011 citations